Alternative Metrics of Response Correlate With OS in FIRE-3 Trial

Share this content:
Alternative metrics of response correlated with the overall survival benefit among patients with RAS wild-type metastatic colorectal cancer.
Alternative metrics of response correlated with the overall survival benefit among patients with RAS wild-type metastatic colorectal cancer.

Alternative metrics of response, such as early tumor shrinkage and depth of response, correlated with the overall survival benefit associated with FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus cetuximab, and with FOLFIRI plus bevacizumab, among patients with RAS wild-type metastatic colorectal cancer (mCRC), according to a study published in The Lancet Oncology.1

This FIRE-3 trial evaluated the efficacy and safety the 2 regimens among patients with KRAS exon 2 wild-type mCRC, including a subgroup of 400 patients with RAS wild-type disease.

In the RAS wild-type subgroup, FOLFIRI plus bevacizumab was associated with 30% reduction in the risk of death, in contrast with FOLFIRI plus cetuximab (hazard ratio, 0.70; 95% CI, 0.54-0.90; P = .0059). Investigator-assessed objective response and progression-free survival, however, were similar between the 2 treatment arms.

Among the 330 CT-assessable patients with RAS wild-type mCRC, the proportion of patients achieving an objective response (P = .0029), frequency of early tumor shrinkage (P = .0005), and median depth of response (P < .0001) were better in those treated with FOLFIRI plus cetuximab.

RELATED: Genetic Picture of Colorectal Cancer Clarified

Early tumor shrinkage and depth of response, as assessed by centralized radiologic review, correlated with the overall survival benefit associated with either of the assessed therapies.

There were no differences in duration of response or time to response between the 2 groups.                

Reference

  1. Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised double-blind phase 3 trial. Lancet Oncol. 2016 Aug 26. doi: 10.1016/S1470-2045(16)30269-8 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters